|
|
Volumn 2008, Issue 3, 2008, Pages 219-226
|
|
Excision repair cross-complementation group 1 enzyme as a molecular determinant of responsiveness to platinum-based chemotherapy for non small-cell lung cancer
a
|
|
Author keywords
Biomarkers; ERCC1; Non small cell lung cancer; Platinum based chemotherapy; Predictive
|
|
Indexed keywords
AZIRIDINE DERIVATIVE;
BIOLOGICAL MARKER;
CARBOPLATIN;
CARMUSTINE;
CHLORAMBUCIL;
CISPLATIN;
DACARBAZINE;
DOCETAXEL;
EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;
FOTEMUSTINE;
GEMCITABINE;
LOMUSTINE;
MELPHALAN;
MESSENGER RNA;
MITOMYCIN C;
NITROSOUREA DERIVATIVE;
OXALIPLATIN;
PLATINUM COMPLEX;
STREPTOZOCIN;
TEMOZOLOMIDE;
TETRAZINE DERIVATIVE;
THIOTEPA;
ANTINEOPLASTIC ACTIVITY;
CANCER ADJUVANT THERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DNA DAMAGE;
DNA REPAIR;
DRUG MECHANISM;
DRUG RESPONSE;
GENE EXPRESSION;
HUMAN;
IMMUNOHISTOCHEMISTRY;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MONOTHERAPY;
NONHUMAN;
PHARMACOGENOMICS;
PROGNOSIS;
PROTEIN EXPRESSION;
REVIEW;
SURVIVAL TIME;
|
|
EID: 42549086234
PISSN: None
EISSN: 11772719
Source Type: Journal
DOI: 10.4137/bmi.s485 Document Type: Review |
|
Times cited : (12)
|
|
References (50)
|
